Ramesh L. Sawant
1* 
, Jyoti B. Wadekar
2, Rushikesh D. Ukirde
1, Ganesh D. Barkade
1 1 Department of Pharmaceutical Chemistry & PG Studies, Dr. Vithalrao Vikhe Patil Foundations College of Pharmacy, Vilad Ghat Ahmednagar-414111, Maharashtra, India.
2 Department of Pharmacognosy, Dr. Vithalrao Vikhe Patil Foundations College of Pharmacy, Vilad Ghat Ahmednagar-414111, Maharashtra, India.
Abstract
Polo-like kinase 1(Plk1) plays an important role in the inhibition of cell proliferation and which is come under the family of serine/threonine-protein kinase. Which is a highly specific target for cancer therapy. In some clinical studies, Plk1 has been identified as a target for cancer. Currently, so many scientists are working on the development of the Plk1 inhibitors and so many scientists and researchers thinking about working on it. Recent strategy for Plk1 inhibition is the development of small molecule inhibitors which will inhibit the Plk1 through the ATP-binding site of the Plk. Now new generation Plk1 inhibitors being tested clinically which are targeting polo box domain. This review highlights the recent progress made in the development of Plk1 inhibitors as anticancer agents.